Related Experiment Videos
[Spironolactone in digitalis-requiring cardiac insufficiency following pacemaker implantation]
Insights
Adding spironolactone to diuretic therapy improved heart failure compensation in patients with pacemakers. This aldosterone antagonist showed benefits where triamterene with thiazide did not.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Severe bradycardiac heart failure with edema in patients with cardiac pacemakers.
- Retrospective study design involving 213 patients.
Purpose:
- To evaluate the effect of adding spironolactone to diuretic therapy in patients with cardiac pacemakers and severe bradycardiac heart failure.
- To compare the efficacy of spironolactone versus triamterene/thiazide in this patient population.
Summary:
- Spironolactone addition to diuretic therapy favorably influenced compensation in 213 patients.
- Benefits were confirmed in 26 patients during drug interruption and in 24 decompensated patients treated with spironolactone.
- Triamterene with a thiazide did not demonstrate a similar positive effect.
Impact:
- Spironolactone is a potentially valuable aldosterone antagonist for managing heart failure in pacemaker patients.
- Findings suggest a targeted therapeutic approach for improved cardiac compensation.
- Highlights the differential efficacy of aldosterone antagonists versus other diuretics in specific heart failure contexts.
Abstract:
In a retrospective study conducted in 213 patients with cardiac pacemakers having severe bradycardiac heart failure with oedema, the addition of the aldosterone-antagonist spironolactone to a diuretic therapy was shown to have a favourable influence on the degree of compensation. This has been confirmed in 26 patients under the conditions of a drug interruption period, and in 24 other patients, who were treated with spironolactone after being decompensated under the therapy with digitalis and diuretic or without diuretic. The application of triamterene with a thiazide did not show this positive effect.